]>
IRCT201108187371N1 IRCT 2011-09-29 Vice chancellory for Research, Zahedan University of Medical Sceiences New regimen of therapy in the treatment of Bronchiolitis Comparison safety and efficacy of Phnylephrine with placebo in treatment of hospitalized children with bronchiolitis 2010-11-22 anticipated 100 Complete https://irct.ir/trial/7817 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 2 bronchiolitis. Intervention 1: First group (A) received routine treatment of bronchiolitis and also received a drop phenyephrin 0.5% in supine position that remained in this position for 1 min. Intervention 2: The second group (B) received routine treatment of bronchiolitis and also recieved drop NaCl 0.9% in supine position that remained in this position for 1 min. Thirty minutes after administration of drug and placebo, O2 saturation, respiratory rate, heart rate, retraction, dyspenea and wheeze were evaluated and scored.
public Marzieh Akbarpour
Department of pediatrics Infectious Disease, Ali ebne Abitaleb Hospital, Khalije Fars High way
Zahedan Iran (Islamic Republic of) +98 54 1341 1260 akbarpoorm@zaums.ac.ir , Pardis_10107@yahoo.com Zahedan University of Medical Sciences scientific Gholamreza Soleimani
Ali ebne Abiteleb Hospital, Zahedan University of Medical Sciences, Khalije Fars High way
Zahedan Iran (Islamic Republic of) +98 54 1341 1260 soleimanigh@zaums.ac.ir Zahedan University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: ages 4 weeks to 12 months; clinical diagnosis of viral bronchiolitis as the primary reason for hospitalization; presence of an oxygen requirement and a minimum severity score of 1. Exclusion criteria: history of chronic neurologic, heart, kidney, or lung disease; history of prematurity <34 weeks gestation; severity score of >10; use of nebulized albuterol or nebulized epinephrine within 4 hours of study enrollment; use of nasal phenylephrine or oxymetazoline within 12 hours of study enrollment; or “unstable” vital signs. “Unstable” vital signs are defined as heart rate >200 beats/min, blood pressure 2 standard deviations above or below the age appropriate mean, and respiratory rate above 80 breaths/min. The choice of maximum score is somewhat arbitrary but would exclude patients with all of the following: respiratory rate ≥70 breaths/min; intercostal, substernal and supraclavicular retractions; no feeding; and inspiratory and expiratory wheezing or diminished breath sounds. no limit 1 year Both J20 acute bronchiolitis Treatment - Drugs Treatment - Drugs First group (A) received routine treatment of bronchiolitis and also received a drop phenyephrin 0.5% in supine position that remained in this position for 1 min. The second group (B) received routine treatment of bronchiolitis and also recieved drop NaCl 0.9% in supine position that remained in this position for 1 min. Thirty minutes after administration of drug and placebo, O2 saturation, respiratory rate, heart rate, retraction, dyspenea and wheeze were evaluated and scored. Respiratory distress. Timepoint: 30 minutes after completion of therapy. Method of measurement: physical examination. Pulse rate. Timepoint: 30 minutes after completion of therapy. Method of measurement: physical examination. O2 saturation. Timepoint: 30 minutes after completion of therapy. Method of measurement: physical examination. Dyspenea. Timepoint: 30 minutes after completion of therapy. Method of measurement: physical examination. Retraction. Timepoint: 30 minutes after completion of therapy. Method of measurement: physical examination. Vice chancellory for Research, Zahedan University of Medical Sceiences Approved 2010-11-28 The ethics committee of Zahedan University of Medical Sceinces Pardis of Zahedan university of medical sciences, Janat bloulovard Zahedan Iran (Islamic Republic of)